Zai

Zai Lab Announces Upcoming Participation in September Conferences

Retrieved on: 
Monday, August 31, 2020
Zai

SHANGHAI and SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will be presenting at the following upcoming virtual conferences in September.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will be presenting at the following upcoming virtual conferences in September.
  • Details of the virtual conferences are as follows:
    Webcast or external link of the company presentations will be available under Events & Presentations in the Investors Relations section of Zai Labs website.
  • Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world.
  • Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas.

Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer

Retrieved on: 
Monday, August 17, 2020
Video games, Zai, Second Life, Video gaming

SHANGHAI and SAN FRANCISCO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that F. Ty Edmondson has been named Chief Legal Officer.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that F. Ty Edmondson has been named Chief Legal Officer.
  • Mr. Edmondson joins Zai Lab from Biogen Inc., a leading global biotech company, where he served as Senior Vice President, Chief Corporation Counsel and Assistant Secretary.
  • Ty brings decades of biopharmaceutical legal and compliance experience, having advised global companies, management teams and boards of directors in a diverse range of markets around the world, said Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab.
  • I am excited to be joining Zai Lab at such an important point in the Companys growth trajectory, said Mr. Edmondson.

Zai Lab Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Updates

Retrieved on: 
Thursday, August 13, 2020
Health, Oncology, Orphan drugs, PARP inhibitors, Gynaecology, Ovarian cancer, RTT, Zai, Niraparib, Medical specialties

In May 2020, Zai Lab announced positive topline results from the NORA Phase 3 study of ZEJULA as maintenance therapy for Chinese patients with platinum-sensitive, recurrent ovarian cancer.

Key Points: 
  • In May 2020, Zai Lab announced positive topline results from the NORA Phase 3 study of ZEJULA as maintenance therapy for Chinese patients with platinum-sensitive, recurrent ovarian cancer.
  • As of June 2020, Zai Lab employed 859 full-time employees, with 366 and 377 employees engaged in R&D and commercial activities, respectively.
  • Valeria Fantin, Chief Scientific Officer, will leave Zai Lab by September 25, 2020 to pursue a new opportunity.
  • Zai Lab will host a live conference call and webcast today, August 13, 2020 at 8:00 a.m.

Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates

Retrieved on: 
Thursday, July 30, 2020
Life sciences, Biotechnology, Articles, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Zai

All participants must use the link provided above to complete the online registration process in advance of the conference call.

Key Points: 
  • All participants must use the link provided above to complete the online registration process in advance of the conference call.
  • Upon registering, each participant will receive a dial-in number, Direct Event passcode, and a unique access PIN, which can be used to join the conference call.
  • Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world.
  • Zai Labs vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China

Retrieved on: 
Tuesday, July 7, 2020
Expense, Intellectual property law, Patent law, Royalty payment, Zai, Companies

Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and commercialize repotrectinib in Greater China and Turning Point Therapeutics will receive a $25 million upfront payment, with potential to receive up to an additional $151 million in development, regulatory and sales-based milestone payments.

Key Points: 
  • Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and commercialize repotrectinib in Greater China and Turning Point Therapeutics will receive a $25 million upfront payment, with potential to receive up to an additional $151 million in development, regulatory and sales-based milestone payments.
  • Turning Point will also be eligible to receive mid-to-high teen royalties based on annual net sales of repotrectinib in Greater China.
  • Our collaboration with Zai Lab is a strategic step to potentially accelerate the development of repotrectinib in Greater China.
  • We are very pleased to enter into this agreement with Turning Point Therapeutics.

Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China

Retrieved on: 
Tuesday, July 7, 2020
Expense, Intellectual property law, Patent law, Royalty payment, Zai, Companies

Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and commercialize repotrectinib in Greater China and Turning Point Therapeutics will receive a $25 million upfront payment, with potential to receive up to an additional $151 million in development, regulatory and sales-based milestone payments.

Key Points: 
  • Under the terms of the agreement, Zai Lab will obtain exclusive rights to develop and commercialize repotrectinib in Greater China and Turning Point Therapeutics will receive a $25 million upfront payment, with potential to receive up to an additional $151 million in development, regulatory and sales-based milestone payments.
  • Turning Point will also be eligible to receive mid-to-high teen royalties based on annual net sales of repotrectinib in Greater China.
  • Our collaboration with Zai Lab is a strategic step to potentially accelerate the development of repotrectinib in Greater China.
  • We are very pleased to enter into this agreement with Turning Point Therapeutics.

Zai Lab Announces Presentations at June Conferences

Retrieved on: 
Wednesday, May 27, 2020
Zai

SHANGHAI and SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that the Company will be presenting at the following upcoming virtual conferences in June.

Key Points: 
  • SHANGHAI and SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that the Company will be presenting at the following upcoming virtual conferences in June.
  • Details of the virtual conferences are as follows:
    Live webcasts of the conferences will be available under "Events & Presentations in the Investors Relations section of Zai Labs website.
  • Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world.
  • Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas.

Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference

Retrieved on: 
Thursday, April 30, 2020
Zai

SHANGHAI, China and SAN FRANCISCO, April 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced that members of management will be presenting at the upcoming BofA Securities 2020 Health Care Conference.

Key Points: 
  • SHANGHAI, China and SAN FRANCISCO, April 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced that members of management will be presenting at the upcoming BofA Securities 2020 Health Care Conference.
  • Presentation details for the virtual conference are as follows:
    A live webcast of the company presentation will be available under "Events & Presentations" in the Investors Relations section of Zai Labs website.
  • Zai Lab (NASDAQ:ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world.
  • Zai Labs vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

Popular Singer and Social Media Star 'Zai' Releases New Studio Album: A Life of Noble Struggle Revealed as 'Stranger Than Fiction'

Retrieved on: 
Friday, April 24, 2020
Digital media, Zai, Social media

Zai is a well-known Florida-based musician and social media personality, recently featured in the " Tampa Bay Times ."

Key Points: 
  • Zai is a well-known Florida-based musician and social media personality, recently featured in the " Tampa Bay Times ."
  • Zai continues to maintain a loyal following of "Zaimbies" who routinely follow both her numerous live performances and studio pieces.
  • "This is me my life, my struggle laid out in song," said Zai.
  • For the latest announcements on live appearances, studio releases, and other news, follow Zai on her thriving social media accounts: Instagram , Facebook .

Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

Retrieved on: 
Wednesday, April 8, 2020
Regeneron Pharmaceuticals, Leverage, Zai, Life sciences, Industries, Biotechnology

Additionally, if REGN1979 is approved, Zai Lab will leverage its capabilities to commercialize REGN1979 in this region.

Key Points: 
  • Additionally, if REGN1979 is approved, Zai Lab will leverage its capabilities to commercialize REGN1979 in this region.
  • Additionally, Zai Lab will make payments to Regeneron based on net sales, such that Regeneron shares in a significant portion of any potential profits.
  • Regeneron will be responsible for the manufacture and supply of REGN1979 for development and commercialization in the region.
  • Zai Lab will host a live conference call and webcast today, April 8, 2020 at 8:00 a.m. EST to discuss the strategic collaboration.